

## Additional file 4



A)



**Supplementary Fig. 3** Time to sustained EDSS progression by ≥2 versus 0–1 active T2 lesions at 6 months.

(a) Placebo/delayed treatment group; (b) IFN β-1a 22 μg SC tiw group; (c) IFN β-1a 44 μg SC tiw group.

A Cox proportional hazards model, adjusted for number of relapses in the previous 2 years, age, baseline EDSS score, and baseline burden of disease, was used to estimate hazard ratios and *p* values. *p* values are for time to first progression over 4 years.

CI: confidence interval; EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly.